Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$881.29 USD

881.29
1,130,837

-4.26 (-0.48%)

Updated Oct 4, 2024 02:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Glaxo (GSK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven third-quarter sales. Although sales of vaccines are likely to have recovered, the impact of the COVID-19 vaccine prioritization may have continued.

Gilead (GILD) to Report Q3 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) third-quarter 2021 results.

Eli Lilly (LLY) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $243.75 in the latest trading session, marking a +1.07% move from the prior day.

Should You Buy Eli Lilly and Company (LLY) Ahead of Earnings?

by Zacks Equity Research

Eli Lilly and Company (LLY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in Store for Teladoc Health's (TDOC) Earnings in Q3?

by Zacks Equity Research

Teladoc Health (TDOC) is likely to report a strong revenue outperformance for the third quarter, driven by broad-based momentum across its business and a sharp acceleration in visit-volume growth.

Radius (RDUS) Up On Positive Data From Breast Cancer Study

by Zacks Equity Research

Radius (RDUS) stock gains in response to positive results from a late-stage study evaluating breast cancer candidate, elacestrant.

Will Eli Lilly (LLY) Surpass Q3 Earnings Expectations?

by Zacks Equity Research

Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.

United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

by Zacks Equity Research

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Lilly (LLY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA

by Zacks Equity Research

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

PFE vs. LLY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PFE vs. LLY: Which Stock Is the Better Value Option?

Pfizer (PFE) Gets CHMP Nod for JAK Inhibitor Abrocitinib

by Zacks Equity Research

The CHMP recommends approving Pfizer (PFE) JAK inhibitors abrocitinib and Xeljanz for the treatment of atopic dermatitis and active ankylosing spondylitis, respectively.

J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector

by Zacks Equity Research

J&J's (JNJ) Pharma segment is expected to have performed above market while market recovery might have benefited Medical Devices segment sales in the third quarter.

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Eli Lilly (LLY) closed at $237.88 in the latest trading session, marking a +0.5% move from the prior day.

Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FLQL

Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FLQL

Roche's (RHHBY) AD Drug Gets Breakthrough Therapy Status

by Zacks Equity Research

Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Cassava (SAVA) Begins First Efficacy Study on Simufilam in AD

by Zacks Equity Research

Cassava (SAVA) starts a phase III efficacy study evaluating simufilam for treating patients with Alzheimer's disease.

Biohaven (BHVN) Q3 Nurtec Preliminary Sales Top Expectations

by Zacks Equity Research

Biohaven's (BHVN) sole marketable drug, Nurtec ODT reports preliminary sales for the third quarter, which beat expectations.

Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study

by Zacks Equity Research

Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.

    AstraZeneca (AZN) Seeks Emergency Nod for COVID Prevention Drug

    by Zacks Equity Research

    If authorized by the FDA, AstraZeneca's (AZN) AZD7442 would be the first long-acting cocktail antibody drug approved for COVID-19 prevention.

    Kinjel Shah headshot

    Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More

    by Kinjel Shah

    Merck (MRK) offers to buy Acceleron Pharma for about $11.5 million. FDA approves AbbVie's (ABBV) new migraine drug, Qulipta.

    The Zacks Analyst Blog Highlights: Eli Lilly, Costco, Applied Materials, Illumina and Norfolk Southern Corp

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Eli Lilly, Costco, Applied Materials, Illumina and Norfolk Southern Corp

    Sheraz Mian headshot

    Top Stock Reports for Eli Lilly, Costco & Applied Materials

    by Sheraz Mian

    Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Costco Wholesale Corporation (COST), and Applied Materials, Inc. (AMAT).